143 related articles for article (PubMed ID: 26285607)
1. Primary RET-mutated lung neuroendocrine carcinoma in MEN2B: response to RET-targeted therapy.
Geiger JL; Chiosea SI; Challinor SM; Nikiforova MN; Bauman JE
Endocr Relat Cancer; 2015 Oct; 22(5):L19-22. PubMed ID: 26285607
[No Abstract] [Full Text] [Related]
2. Hereditary Medullary Thyroid Cancer Genotype-Phenotype Correlation.
Frank-Raue K; Raue F
Recent Results Cancer Res; 2015; 204():139-56. PubMed ID: 26494387
[TBL] [Abstract][Full Text] [Related]
3. Use of Tyrosine Kinase Inhibitors for Treatment of Medullary Thyroid Carcinoma.
Dadu R; Hu MN; Grubbs EG; Gagel RF
Recent Results Cancer Res; 2015; 204():227-49. PubMed ID: 26494392
[TBL] [Abstract][Full Text] [Related]
4. RET proto-oncogene mutations are restricted to codons 634 and 918 in mainland Chinese families with MEN2A and MEN2B.
Zhou Y; Zhao Y; Cui B; Gu L; Zhu S; Li J; Liu J; Yin M; Zhao T; Yin Z; Yu C; Chen C; Wang L; Xiao B; Hong J; Zhang Y; Tang Z; Wang S; Li X; Ning G
Clin Endocrinol (Oxf); 2007 Oct; 67(4):570-6. PubMed ID: 17573899
[TBL] [Abstract][Full Text] [Related]
5. Generation of an induced pluripotent stem cell line from a patient with hereditary multiple endocrine neoplasia 2B (MEN2B) syndrome with "highest risk" RET mutation.
Bennaceur-Griscelli A; Hadoux J; Féraud O; Opolon P; Divers D; Gobbo E; Schlumberger M; Griscelli F; Turhan AG
Stem Cell Res; 2017 Aug; 23():154-157. PubMed ID: 28925363
[TBL] [Abstract][Full Text] [Related]
6. Prostate adenocarcinoma in a young patient with multiple endocrine neoplasia 2B.
Maqdasy S; Costes-Chalret N; Batisse-Lignier M; Baron S; Tauveron I
Ann Endocrinol (Paris); 2018 Apr; 79(2):86-89. PubMed ID: 29530270
[No Abstract] [Full Text] [Related]
7. Novel tandem germline RET proto-oncogene mutations in a patient with multiple endocrine neoplasia type 2B: report of a case and a literature review of tandem RET mutations with in silico analysis.
Nakao KT; Usui T; Ikeda M; Mori Y; Yamamoto T; Kawashima ST; Nanba K; Yuno A; Tamanaha T; Tagami T; Naruse M; Asato R; Shimatsu A
Head Neck; 2013 Dec; 35(12):E363-8. PubMed ID: 23468374
[TBL] [Abstract][Full Text] [Related]
8. How should "RET positive" NSCLC be treated?
Smit EF
Lung Cancer; 2017 Jun; 108():250-251. PubMed ID: 28189265
[No Abstract] [Full Text] [Related]
9. A comprehensive review on MEN2B.
Castinetti F; Moley J; Mulligan L; Waguespack SG
Endocr Relat Cancer; 2018 Feb; 25(2):T29-T39. PubMed ID: 28698189
[TBL] [Abstract][Full Text] [Related]
10. Aggressive medullary thyroid carcinoma in a ten-year-old patient with multiple endocrine neoplasia 2B due to the A883F mutation.
Mathiesen JS; Stochholm K; Poulsen PL; Vestergaard EM; Christiansen P; Vestergaard P
Thyroid; 2015 Jan; 25(1):139-40. PubMed ID: 25244518
[No Abstract] [Full Text] [Related]
11. Mutations in the RET proto-oncogene in medullary thyroid carcinoma.
Höppner W
Clin Lab; 2007; 53(5-6):283-4. PubMed ID: 17605402
[No Abstract] [Full Text] [Related]
12. Comprehensive Genomic Profiling of Clinically Advanced Medullary Thyroid Carcinoma.
Heilmann AM; Subbiah V; Wang K; Sun JX; Elvin JA; Chmielecki J; Sherman SI; Murthy R; Busaidy NL; Subbiah I; Yelensky R; Nangia C; Vergilio JA; Khan SA; Erlich RL; Lipson D; Ross JS; Miller VA; Shah MH; Ali SM; Stephens PJ
Oncology; 2016; 90(6):339-46. PubMed ID: 27207748
[TBL] [Abstract][Full Text] [Related]
13. Combination chemotherapy with 5-fluorouracil and dacarbazine in advanced medullary thyroid cancer, a possible alternative?
Marchand L; Nozières C; Walter T; Descotes F; Decaussin-Petrucci M; Joly MO; Lapras V; Bournaud C; Borson-Chazot F
Acta Oncol; 2016 Aug; 55(8):1064-6. PubMed ID: 27173015
[No Abstract] [Full Text] [Related]
14. Transcriptome analysis in mouse tumors induced by Ret-MEN2/FMTC mutations reveals subtype-specific role in survival and interference with immune surveillance.
Engelmann D; Koczan D; Ricken P; Rimpler U; Pahnke J; Li Z; Pützer BM
Endocr Relat Cancer; 2009 Mar; 16(1):211-24. PubMed ID: 18984779
[TBL] [Abstract][Full Text] [Related]
15. Pralsetinib: First Approval.
Markham A
Drugs; 2020 Nov; 80(17):1865-1870. PubMed ID: 33136236
[TBL] [Abstract][Full Text] [Related]
16. Molecular mechanisms of RET receptor-mediated oncogenesis in multiple endocrine neoplasia 2B.
Gujral TS; Singh VK; Jia Z; Mulligan LM
Cancer Res; 2006 Nov; 66(22):10741-9. PubMed ID: 17108110
[TBL] [Abstract][Full Text] [Related]
17. The development of rapid and accurate screening test for RET hotspot somatic and germline mutations in MEN2 syndromes.
Zupan A; Glavač D
Exp Mol Pathol; 2015 Dec; 99(3):416-25. PubMed ID: 26321248
[TBL] [Abstract][Full Text] [Related]
18. Selpercatinib.
Am J Health Syst Pharm; 2020 Oct; 77(22):1818-1821. PubMed ID: 32930710
[No Abstract] [Full Text] [Related]
19. [Hereditary medullary thyroid cancer in a family with MEN2B: clinical analysis and mutation detection of RET proto-oncogene].
Zhang Y; Zhang B; Liu W; Yang L; Xu Z
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2014 May; 49(5):422-4. PubMed ID: 25017234
[No Abstract] [Full Text] [Related]
20. RET kinase inhibitors: a review of recent patents (2012-2015).
Mologni L; Gambacorti-Passerini C; Goekjian P; Scapozza L
Expert Opin Ther Pat; 2017 Jan; 27(1):91-99. PubMed ID: 27646564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
